JNJ

237.95

-0.85%↓

UNH

279.65

+1.17%↑

TMO

544.46

+0.45%↑

ABT

110.96

+0.13%↑

ISRG

491.2

+0.81%↑

JNJ

237.95

-0.85%↓

UNH

279.65

+1.17%↑

TMO

544.46

+0.45%↑

ABT

110.96

+0.13%↑

ISRG

491.2

+0.81%↑

JNJ

237.95

-0.85%↓

UNH

279.65

+1.17%↑

TMO

544.46

+0.45%↑

ABT

110.96

+0.13%↑

ISRG

491.2

+0.81%↑

JNJ

237.95

-0.85%↓

UNH

279.65

+1.17%↑

TMO

544.46

+0.45%↑

ABT

110.96

+0.13%↑

ISRG

491.2

+0.81%↑

JNJ

237.95

-0.85%↓

UNH

279.65

+1.17%↑

TMO

544.46

+0.45%↑

ABT

110.96

+0.13%↑

ISRG

491.2

+0.81%↑

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Avatud

SektorTervishoid

1.11 -1.77

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.07

Max

1.13

Põhinäitajad
By Trading Economics
Sissetulek	1.8M -32M
Müük	-166K 1.7M
Kasumimarginaal	-1,852.384
Töötajad	181
EBITDA	7.9M -29M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+328.07% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	3. märts 2026

Turustatistika
By TradingEconomics
Turukapital	16M 142M
Eelmine avamishind	2.88
Eelmine sulgemishind	1.11

Uudiste sentiment

By Acuity

50%

139 / 352 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

8. veebr 2026, 23:57 UTC

Market Talk

Uranium Outlook Heats Up on Rising Demand, Uncertain Supply -- Market Talk

8. veebr 2026, 23:47 UTC

Market Talk

Gold Rises Amid Growing U.S.-Iran Tensions -- Market Talk

8. veebr 2026, 23:43 UTC

Market Talk

Nikkei Likely to Rise Sharply After Takaichi's Election Win -- Market Talk

8. veebr 2026, 23:34 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8. veebr 2026, 23:34 UTC

Market Talk

Landslide Election Victory of Japan's LDP Positive for Risk Assets -- Market Talk

8. veebr 2026, 23:26 UTC

Market Talk

Yen Skittish; Nikkei Jumps On LDP Landslide -- Market Talk

8. veebr 2026, 22:55 UTC

Tulu

DBS Group 4Q Net S$2.36B Vs. Net S$2.62B >D05.SG

8. veebr 2026, 22:55 UTC

Tulu

DBS Group 4Q Net Interest Income S$3.59B Vs. S$3.83B>D05.SG

8. veebr 2026, 22:55 UTC

Tulu

DBS Board Proposes 4Q Dividend of 66 Singapore Cents/share>D05.SG

8. veebr 2026, 22:55 UTC

Tulu

DBS Group: 2025 Total Dividend at S$3.06/share >D05.SG

8. veebr 2026, 22:55 UTC

Tulu

DBS Group 4Q Net Weighed by Higher Tax Expense, Absence of Non-Recurring Gains Recrorded Last Year >D05.SG

8. veebr 2026, 22:55 UTC

Tulu

DBS Group 4Q Total Income S$5.33B Vs. S$5.51B>D05.SG

8. veebr 2026, 21:43 UTC

Market Talk

FX Intervention Watch Resumes After Japan Election Result -- Market Talk

8. veebr 2026, 21:16 UTC

Market Talk

Right Of Australian Politics Reshaped as One Nation Surges -- Market Talk

8. veebr 2026, 21:15 UTC

Market Talk

Japan's Election Outcome to Revive Takaichi Trade -- Market Talk

7. veebr 2026, 09:20 UTC

Market Talk

Financial Services Roundup: Market Talk

7. veebr 2026, 09:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

7. veebr 2026, 05:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

7. veebr 2026, 02:46 UTC

Omandamised, ülevõtmised, äriostud

Big Money, High Anxiety -- Barrons.com

6. veebr 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

6. veebr 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

6. veebr 2026, 21:40 UTC

Omandamised, ülevõtmised, äriostud

Verizon Insiders Rarely Sell Company Stock. This Insider Just Did. -- Barrons.com

6. veebr 2026, 21:22 UTC

Market Talk

Mexico's Inflation Seen Accelerating in January -- Market Talk

6. veebr 2026, 21:17 UTC

Tulu

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6. veebr 2026, 21:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6. veebr 2026, 21:14 UTC

Omandamised, ülevõtmised, äriostud

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- Update

6. veebr 2026, 21:13 UTC

Tulu

How the Software Panic Hit BDC Stocks -- and Why Some Might Be Worth Buying -- Barrons.com

6. veebr 2026, 21:13 UTC

Tulu

Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More Stock Market Movers -- Barrons.com

6. veebr 2026, 21:04 UTC

Market Talk

Gold Closes Out Volatile Week on Higher Note -- Market Talk

6. veebr 2026, 20:34 UTC

Tulu

Tech Had an Awful Earnings Season. Other Stocks Are Saving the Day. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

328.07% tõus

12 kuu keskmine prognoos

Keskmine 4.88 USD 328.07%

Kõrge 8 USD

Madal 2 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

6 ratings

Osta

Hoia

Müü

Põhineb 6 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

139 / 352 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.